Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies.
ADC drugs have both the powerful killing effects of the small molecule and tumor targeting properties of antibody. The recent technology breakthrough has led to nine new ADC approvals in the past three years for cancer treatment.
As one of the most sophisticated class of drug modalities, ADC has several components including antibody, payload and linkers with a concerted mechanism of functions. New structures are emerging regularly to hit the new clinical applications, and the indications are also moving rapidly from oncology to non-oncology fields.
MediLink Therapeutics was formed by experienced scientists from both small and large molecule drug development fields. The management team has collectively put over 20 new compounds into clinical developments, 3 of them are antibody drug conjugates. The team also has strong background in corporate governance and capital operations.
